Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 7, 2008, Pages 2507-2514

  Utz, Andrea L ^a   Yamamoto, Ami ^a   Hemphill, Linda ^a   Miller, Karen K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; C REACTIVE PROTEIN; CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR I; TUMOR NECROSIS FACTOR ALPHA RECEPTOR II;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; HYPOPITUITARISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 47549103137     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-0169     Document Type: Article

References (52)

1. Bates AS, Van't Hoff W, Jones PJ, Clayton RN 1996 The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 81:1169-1172
2. Bulow B, Hagmar L, Eskilsson J, Erfurth EM 2000 Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. J Clin Endocrinol Metab 85:574-584
3. Rosen T, Bengtsson BA 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285-288
4. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM 2001 Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357:425-431
5. Wuster C, Slenczka E, Ziegler R 1991 [Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: need for additional growth hormone substitution?]. Klin Wochenschr 69:769-773
6. Borson-Chazot F, Serusclat A, Kalfallah Y, Ducottet X, Sassolas G, Bernard S, Labrousse F, Pastene J, Sassolas A, Roux Y, Berthezene F 1999 Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. J Clin Endocrinol Metab 84:1329-1333
7. Capaldo B, Patti L, Oliviero U, Longobardi S, Pardo F, Vitale F, Fazio S, Di Rella F, Biondi B, Lombardi G, Sacca L 1997 Increased arterial intima-media thickness in childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 82:1378-1381
8. Evans LM, Davies JS, Goodfellow J, Rees JA, Scanlon MF 1999 Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clin Endocrinol (Oxf) 50:457-464
9. Johansson JO, Landin K, Tengborn L, Rosen T, Bengtsson BA 1994 High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb 14:434-437
10. Leonsson M, Hulthe J, Oscarsson J, Johannsson G, Wendelhag I, Wikstrand J, Bengtsson BA 2002 Intima-media thickness in cariovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors. Clin Endocrinol (Oxf) 57:751-759
11. Markussis V, Beshyah SA, Fisher C, Sharp P, Nicolaides AN, Johnston DG 1992 Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 340:1188-1192
12. Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN 1999 Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 84:453-457
13. Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson BA 1993 Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 129:195-200
14. Sesmilo G, Miller KK, Hayden D, Klibanski A 2001 Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab 86:5774-5781
15. Bollerslev J, Ueland T, Jorgensen AP, Fougner KJ, Wergeland R, Schreiner T, Burman P 2006 Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol 154:537-543
16. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA 1997 Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 82:550-555
17. Johansson JO, Landin K, Johannsson G, Tengborn L, Bengtsson BA 1996 Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb Haemost 76:422-428
18. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P 2004 Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 89:2192-2199
19. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A 2000 Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 133:111-122
20. Carmichael JD, Danoff A, Milani D, Roubenoff R, Lesser ML, Livote E, Reitz RE, Ferris S, Kleinberg DL 2006 GH peak response to GHRH-arginine: relationship to insulin resistance and other cardiovascular risk factors in a population of adults aged 50-90. Clin Endocrinol (Oxf) 65:169-177
21. Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V, Stavrou S, Kleinberg DL, Chipman JJ, Hartman ML 2002 Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 87:2067-2079
22. Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S 2004 Growth hormone-releasing hormone in HIV-infectedmenwith lipodystrophy. JAMA 292:210-218
23. Kratz A, Ferraro M, Sluss P, Lewandrowski K 2004 Laboratory reference values. N Engl J Med 351:1548-1563
24. Corneli G, Di Somma C, Baldelli R, Rovere S, Gasco V, Croce CG, Grottoli S, Maccario M, Colao A, Lombardi G, Ghigo E, Camanni F, Aimaretti G 2005 The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 153:257-264
25. Ho KK 2007 Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157:695-700
26. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon 3rd RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith Jr SC, Taubert K, Tracy RP, Vinicor F 2003 Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511
27. Besson A, Salemi S, Gallati S, Jenal A, Horn R, Mullis PS, Mullis PE 2003 Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab 88:3664-3667
28. Erfurth EM, Bulow B, Eskilsson J, Hagmar L 1999 High incidence of cardiovascular disease and increased prevalence of cardiovascular risk factors in women with hypopituitarism not receiving growth hormone treatment: preliminary results. Growth Horm IGF Res 9(Suppl A):21-24
29. Buijs MM, Burggraaf J, Wijbrandts C, de Kam ML, Frolich M, Cohen AF, Romijn JA, Sauerwein HP, Meinders AE, Pijl H 2003 Blunted lipolytic response to fasting in abdominally obese women: evidence for involvement of hyposomatotropism. Am J Clin Nutr 77:544-550
30. Kanaley JA, Weatherup-Dentes MM, Jaynes EB, Hartman ML 1999 Obesity attenuates the growth hormone response to exercise. J Clin Endocrinol Metab 84:3156-3161
31. Marin P, Kvist H, Lindstedt G, Sjostrom L, Bjorntorp P 1993 Low concentrations of insulin-like growth factor-I in abdominal obesity. Int J Obes Relat Metab Disord 17:83-89
32. Miller KK, Biller BM, Lipman JG, Bradwin G, Rifai N, Klibanski A 2005 Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J Clin Endocrinol Metab 90:768-774
33. Pijl H, Langendonk JG, Burggraaf J, Frolich M, Cohen AF, Veldhuis JD, Meinders AE 2001 Altered neuroregulation of GH secretion in viscerally obese premenopausal women. J Clin Endocrinol Metab 86:5509-5515
34. Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML, Lizarralde G 1991 Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 72:51-59
35. Weltman A, Despres JP, Clasey JL, Weltman JY, Wideman L, Kanaley J, Patrie J, Bergeron J, Thorner MO, Bouchard C, Hartman ML 2003 Impact of abdominal visceral fat, growth hormone, fitness, and insulin on lipids and lipoproteins in older adults. Metabolism 52:73-80
36. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK 1999 Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14-22
37. Ridker P, Rifai N, Rose L, Buring J, Cook N 2002 Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. 2002 347:1557-1565
38. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH 1997 Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979
39. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM 2002 Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 288:980-987
40. Maccario M, Ramunni J, Oleandri SE, Procopio M, Grottoli S, Rossetto R, Savio P, Aimaretti G, Camanni F, Ghigo E 1999 Relationships between IGF-1 and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. Int J Obes Relat Metab Disord 23:612-618
41. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A 2001 The somatomedin hypothesis: 2001. Endocr Rev 22:53-74
42. Butler AA, Le Roith D 2001 Control of growth by the somatropic axis: growth hormone and the insulin-like growth factors have related and independent roles. Annu Rev Physiol 63:141-164
43. Clemmons DR 2004 The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest 113:25-27
44. Hussain MA, Schmitz O, Mengel A, Glatz Y, Christiansen JS, Zapf J, Froesch ER 1994 Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. J Clin Invest 94:1126-1133
45. Dietz J, Schwartz J 1991 Growth hormone alters lipolysis and hormone-sensitive lipase activity in 3T3-F442A adipocytes. Metabolism 40:800-806
46. Franco C, Andersson B, Lonn L, Bengtsson BA, Svensson J, Johannsson G 2007 Growth hormone reduces inflammation in postmenopausal women with abdominal obesity: a 12-month, randomized, placebo-controlled trial. J Clin Endocrinol Metab 92:2644-2647
47. Franco C, Brandberg J, Lonn L, Andersson B, Bengtsson BA, Johannsson G 2005 Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab 90:1466-1474
48. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L, Bengtsson BA 1997 Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82:727-734
49. Albert SG, Mooradian AD 2004 Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity. J Clin Endocrinol Metab 89:695-701
50. Albert SG, Haas MJ, Mooradian AD 2007 The effects of recombinant human growth hormone (rhGH) supplementation on adipokines and C-reactive protein in obese subjects. Growth Horm IGF Res 17:19-25
51. Ahn CW, Kim CS, Nam JH, Kim HJ, Nam JS, Park JS, Kang ES, Cha BS, Lim SK, Kim KR, Lee HC, Huh KB 2006 Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control. Clin Endocrinol (Oxf) 64:444-449
52. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR 2002 Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-1565